LexBlog IP

DECEMBER 13, 2023

The post Janssen and Samsung Bioepis Settle STELARA (Ustekinumab) Litigation appeared first on Big Molecule Watch.

Litigation 52

Litigation Settlement Licensing Marketing 52

SpicyIP

JULY 8, 2024

Here is our recap of last week’s top IP developments including summary of the posts on the DHC’s direction to frame a code of conduct for Patent and Trademark Agents, MHC’s decision on prior arts, and the settlement between Dabur and Dhruv Rathee of their trademark and copyright dispute. Anything we are missing out on?

Invention 59

Invention Art Trademark Patent Application 59

SpicyIP

MARCH 15, 2024

Since parties could not arrive at a settlement, ID initiated patent infringement proceedings against the defendants in UK, Germany and India. If the trial spills over to 2025, the defendants will have to bear the cost for that as well. The parties commenced joint negotiations in 2021.

Patent Infringement 59

Patent Infringement Settlement Patent Licensing 59

LexBlog IP

NOVEMBER 5, 2023

The licensure and marketing of WEZLANA could affect negotiations with CMS regarding Medicare pricing for STELARA under the Inflation Reduction Act’s Drug Price Negotiation Program. According to a reported statement from Amgen, its settlement agreement with Janssen allows Amgen to sell WEZLANA “no later than January 1, 2025.”

Marketing 40

Marketing Marketing Government Litigation 40

Biswajit Sarkar Copyright Blog

DECEMBER 19, 2023

As India aims for a $5 trillion economy, the MSME ministry sets ambitious goals, aiming to elevate their GDP contribution by up to 50% by 2025. MSMEs foster innovation by nurturing aspiring entrepreneurs, encouraging the development of innovative goods that enhance market competitiveness and fuel sustained growth.

Settlement 52

Settlement Intellectual Property Registration Design 52

LexBlog IP

JANUARY 25, 2024

The licensure and marketing of WEZLANA could affect negotiations with CMS regarding Medicare pricing for STELARA under the Inflation Reduction Act’s Drug Price Negotiation Program. According to a reported statement from Amgen, its settlement agreement with Janssen allows Amgen to sell WEZLANA “no later than January 1, 2025.”

Marketing 40

Marketing Marketing Licensing Litigation 40

Fish & Richardson Trademark & Copyright Thoughts

FEBRUARY 4, 2021

At the same time, market uptake of biosimilars in the United States continued to increase, suggesting that there is room for expansion of biosimilars in the U.S. In addition, fewer new biosimilars entered the market this past year, with five biosimilar launches in 2020 as compared to seven in 2019. January 2021. off ASP and 23.7%

Litigation 52

Litigation Settlement Marketing Marketing 52

LexBlog IP

FEBRUARY 23, 2024

On February 15, Alvotech announced that it reached more settlement agreements with Johnson & Johnson for ATV04, Alvotech’s biosimilar to STELARA (ustekinumab). Alvotech has commercial partners for AVT04 in each of the aforementioned markets. Per the settlement agreement, AVT04 can be marketed in the U.S.,

Settlement 40

Settlement Marketing Marketing Licensing 40